New drug fezolinetant tested for hot flash relief in everyday life
NCT ID NCT07602530
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows Canadian women in menopause who are prescribed fezolinetant by their own doctors for hot flashes and night sweats. Over 1 year, researchers track how well the drug improves symptoms, sleep, and well-being, as well as any side effects. It's a real-world look at how the treatment works outside of a controlled lab setting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fezolinetant (VEOZAH)
What this could lead to
If successful, this study could confirm that fezolinetant effectively reduces hot flashes and night sweats in real-world settings, improving sleep and quality of life for menopausal women.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It only includes Canadian women, and outcomes depend on patient reports, which can vary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HOT FLASHES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site CA15001
RECRUITINGPrince Albert, Canada
-
Site CA15002
RECRUITINGMontreal, Canada